At Nephron Research, our mission is to be essential to our clients’ investment process.
As the market’s leading independent healthcare equity research provider, we strive to separate market noise from the insights that are essential to the investment process.
Nephron’s primary differentiators lie in our research teams and their approach to equity research. The deep experience and insight of our analysts as well as an intense drive to serve a discerning client base sets us apart. With the sole focus of creating value for clients, Nephron can provide a depth of coverage, breadth of access, and consultative services that traditional models lack.
Delivered via an independent and unbiased subscription-only model, Nephron is directly aligned with our client’s interests and investment processes
Meet The Team
At Nephron Research, our experience and connectivity drive deep research products which is supplemented by hyper-relevant corporate access
Process Drives We tackle the most important debates, react quickly, and provide leading perspective
NEPHRON RESEARCH COVID-19 Daily Tracker: June 3, 2020; Hot Spots - States
Download
HMOs and Hospitals: 20 Questions and 20 Answers to Quantify the COVID19 Impact
Download
A Closer Look: COVID-19 Script Declines Represent an Acute, Not Chronic, Problem
DownloadNephron Research Curates Dozens of Events Each Year Designed for Maximum Impact to Client Investment Process
Josh Raskin and team believe that the next era of healthcare will be defined by the trend of physician enablement whereby companies will be able to benefit from the value created through risk based contracts. Josh will host his second symposium assembling a full day of panels with thought leaders and expert practitioners to dissect and discuss this emerging segment of healthcare.
Preparing for Humira + New and Disruptive Models. Confirmed Participants: Cigna/Evernorth, Prime Therapeutics, Evio + BCBS of Michigan, Emsana + The Purchaser Business Group on Health, Capital Rx, EQRx, Vizient, Mercer Health & Benefits, and many more…
The second annual LBx Symposium where Jack Meehan will host both public and private companies alongside experts in the field.
Our independent model and deep healthcare and investment expertise allows us to deliver a full suite of bespoke
and consultative services to investment firms and market participants.
The 2022 Benefit Innovation Symposium will center on three key topics:
Preparing for Humira: We will examine PBM, Payor and Employer biosimilar strategies for 2023 and beyond.
Rebate Contracting Entities: A deep dive into Cigna’s Ascent and Prime’s emergence as the aggregator of aggregators.
New & Disruptive Models: Our picks for potential disruption: ‘New Payor’ (Evio), ‘New PBM’ (Emsana, Mark Cuban Cost Plus Drug Company, & CapitalRx), ‘New Pharma’ (EQRx & Biosim Mfrs.), and many more…
